[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627087":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":54,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":90,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"National University of Singapore","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NOVI Health weight management cohort",null,"Adults newly enrolled in the NOVI Health weight management program receiving standard-of-care GLP-1 receptor agonist therapy (semaglutide or tirzepatide) and lifestyle coaching (diet and physical activity) as part of routine clinical care. Medication type is determined by routine clinical care and patient-clinician decision-making, not by the research study.",[13],"Other: Not applicable. This is an observational study.",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Not applicable. This is an observational study.",[9],[19],{"name":20,"affiliation":5,"role":21},"Jan Gruber, PhD","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Zhi Meng Lim, MSc","CONTACT","+65 90084510","zmlim@nus.edu.sg",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Hui Ching Michelle Lee, PhD","michelle.lee@novi-health.com",[32,49],{"facility":33,"status":10,"city":34,"state":10,"zip":35,"country":34,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"NOVI Health (T3 Health PTE LTD)","Singapore","068914","SG",{"type":38,"coordinates":39},"Point",[40,41],103.85007,1.28967,{"lat":41,"lon":40},[44,46],{"name":29,"role":25,"phone":45,"phoneExt":10,"email":30},"+65 82822765",{"name":47,"role":48,"phone":10,"phoneExt":10,"email":10},"Sue-Anne Ee Shiow Toh, MA MBBChir MSc","SUB_INVESTIGATOR",{"facility":5,"status":10,"city":34,"state":10,"zip":50,"country":34,"countryCode":36,"cosmosGeoPoint":51,"geoPoint":53,"contacts":10},"119077",{"type":38,"coordinates":52},[40,41],{"lat":41,"lon":40},{"type":21,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jan Gruber","Associate Professor",[58],{"name":59,"class":60},"T3 Health PTE LTD","UNKNOWN","100627087","assessing-biological-aging-in-a-real-world-medical-weight-loss-program-using-the-linage2-clinical-clock-100627087",false,"NCT07444073","Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","Inclusion Criteria\n\n* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.\n* BMI of ≥ 30 kg\u002Fm2 (obesity); OR\n* BMI of ≥ 27 kg\u002Fm2 to \\\u003C 30 kg\u002Fm2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.\n\nExclusion Criteria\n\n* Pregnancy or lactation.\n* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.\n* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.\n* On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.\n* Active cancer on chemotherapy or immunotherapy.\n* Known hypersensitivity or contraindications to GLP-1 RAs.\n* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.","ALL","40 Years","89 Years",{"count":71,"type":72},440,"ESTIMATED","OBSERVATIONAL","This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.",[76,77],"Aging","Obesity & Overweight",[79,80,81,82,83,84,85,86,87,88,89],"LinAge2","Biological Age","GLP-1 Receptor Agonist","Semaglutide","Tirzepatide","Weight Management Program","Lifestyle","Real-World Evidence","Cardiometabolic Biomarkers","Body Composition","Prospective Cohort","NOT_YET_RECRUITING","2026-06-29",{"date":93,"type":94},"2026-07-01","ACTUAL",{"date":96,"type":72},"2026-06-01",{"date":98,"type":72},"2027-12-31",{"name":5,"class":6},2]